$BEAM

S&P 500 holds near records despite $100+ oil, weak breadth, and consumer softening, as AI strength masks broader market fragmentation.

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.

Global DNA read, write, edit market projected to surge from $21.4B in 2024 to $67.7B by 2030, driven by CRISPR advances and genomic diagnostics expansion.

Beam Therapeutics reports positive Phase 1/2 data for BEAM-302 base editing therapy in alpha-1 antitrypsin deficiency, advancing toward pivotal development in late 2026.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.

Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.

Beam Therapeutics will discuss 2025 results and unveil a new liver disease program on February 24, 2026. The company also secured FDA alignment for accelerated approval of BEAM-302.